This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Xifaxan

Valeant Pharmaceuticals International, Inc.

Drug Names(s): rifaximin, Normix (Italy), Refero, Spiraxin (Spain), Targaxan, Tixteller, Zaxine (Canada), Rifxima (Japan)

Description: Rifaximin is a structural analog of rifampin; it acts by binding the beta-subunit of bacterial DNA-dependent RNA polymerase resulting in the inhibition of bacterial RNA synthesis.

Deal Structure: Revenue splits are BioMedTracker estimates

United States and Canada
In June 1996, Salix entered into a license agreement with Alfa Wassermann pursuant to which Alfa Wassermann licensed to Salix the exclusive rights to make, use and sell rifaximin (Xifaxan) in the United States and Canada for the treatment of gastrointestinal and respiratory tract diseases. Pursuant to the license agreement, Salix agreed to pay Alfa Wassermann a net sales-based royalty, as well as milestone payments. Salix made annual milestone payments in varying amounts to Alfa Wassermann until the commercial launch of Xifaxan in July 2004. No more milestone payments remain under this agreement. The obligation to pay royalties commenced upon the commercial launch of the product and continues until the later of (1) the expiration of the period in which the manufacture, use or sale of the products by an unlicensed third party would constitute an infringement on the patent covering the product...See full deal structure in Biomedtracker

Partners: Alfa Wassermann SpA Norgine B.V. Aska Pharmaceutical Company Limited


Xifaxan News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug